| War Paint to Bone Paint: MIT Spinout Aims to Transform Regenerative Meds | Dan Stanton | 04/21/20 | Boston |
| Japan’s Kyowa Kirin Pays MEI Pharma $100M in Blood Cancer Drug Pact | Sarah de Crescenzo | 04/14/20 | National |
| Creating Consistent Value in Biotech Without Diluting Stakeholders | Alexis Peyroles | 04/07/20 | National |
| Vir Advances Antibodies Against COVID-19, CEO Leads BIO’s Coronavirus Outreach | Mandy Jackson | 04/02/20 | National |
| Tapping Into the Innovation Grid: J&J, Data, and a Shifting Healthcare Focus | Dan Stanton | 03/31/20 | Europe |
| Axsome Plans to Try Again After Failure in Treatment-Resistant Depression | Frank Vinluan | 03/30/20 | New York |
| Lax Approval Requirements Yield Blockbusters That Don’t Work | Andy Smith | 03/13/20 | National |
| UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System | Ian Schofield | 02/25/20 | Europe |
| New Meds Set to Reshape US CNS and Oncology Markets | Gareth Macdonald | 02/18/20 | National |
| CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019 | Dan Stanton | 02/12/20 | National |
| UK Startups Double in Number Backed By Larger Scale Investments: Report | Melissa Fassbender | 01/09/20 | Europe |
| The Placebo Effect Is Hobbling New Psychiatric Drugs. What Can Stop It? | Alex Lash | 10/10/19 | National |
| Five Years After Y Combinator First Admits Biotechs, They’re Dug In | Bernadette Tansey | 10/09/19 | San Francisco |
| Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels | Frank Vinluan | 10/07/19 | National |
| Akcea, Fresh Off C-Suite Shakeup, Dishes Heart Drug to Pfizer for $250M | Ben Fidler | 10/07/19 | Boston |
| Bio Roundup: PARP Progress, A New Commish, IPO-Palooza & More | Ben Fidler | 10/04/19 | National |
| Meissa Scores $30M to Test Vaccine for Dangerous Respiratory Virus | Bernadette Tansey | 09/26/19 | San Francisco |
| Enanta Steps Forward in NASH Race, With Unclear Prospects | Ben Fidler | 09/26/19 | Boston |
| Drug Pricing: Innovation, Investment, and the Public Good | Johannes Fruehauf | 09/24/19 | Boston |
| Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More | Ben Fidler | 09/13/19 | National |
| Herceptin Inventors, Immunology Pioneers Take Home 2019 Lasker Awards | Ben Fidler | 09/10/19 | National |
| With FDA’s Eye on JAK Drugs, Concert Moves One Ahead For Hair Loss | Ben Fidler | 09/03/19 | Boston |
| Retrophin Sinks as Drug “Pharma Bro” Martin Shkreli Co-Invented Fails | Ben Fidler | 08/22/19 | San Diego |
| FDA Rejects Sarepta’s Second Duchenne Drug, Citing Safety Concerns | Ben Fidler | 08/19/19 | Boston |
| Four New Drugs Are Around the Corner. Here’s What You Need to Know. | Ben Fidler | 08/15/19 | National |
| Bayer Buys Out BlueRock, Betting at Least $240M More on Cell Therapy Work | Ben Fidler | 08/08/19 | Boston |
| Women’s Health-Focused Luca Bio Takes Microbiome R&D Beyond the Gut | Sarah de Crescenzo | 08/06/19 | Boston |
| Another Delay for Intra-Cellular as FDA Extends Review of Psych Drug | Frank Vinluan | 08/05/19 | New York |
| GlycoMimetics Sickle Cell Drug Flops as Others Creep Forward | Ben Fidler | 08/05/19 | New York |
| Mark Levin Named Xconomy’s 2019 Lifetime Achievement Award Winner in Boston | Angela Shah | 07/31/19 | National |
